Drug-eluting Balloon for Treatment of Non-atherosclerotic Renal Artery Stenosis

  • End date
    Oct 1, 2023
  • participants needed
  • sponsor
    Peking Union Medical College Hospital
Updated on 24 January 2021


Efficacy of drug eluting balloon(DEB) for non-atherosclerotic renal artery stenosis will be tested in this study. The intervention group will be treated with paclitaxel eluting balloon. The control group will be treated with plain old balloon(POB). The primary endpoint is efficacy of blood pressure control.


Renal artery stenosis is common cause for hypertension in young people. It could be treated with open surgery or endovascular intervention. Open surgery has relatively high complication rate. Endovascular intervention is micro-invasive but with high restenosis rate. Drug eluting balloon(DEB) has been demonstrated to be effective for preventing restenosis in peripheral arteries. This study aims to test the efficacy of drug eluting balloon for non-atherosclerotic renal artery stenosis. The intervention group will be treated with paclitaxel eluting balloon. The control group will be treated with plain old balloon. The primary endpoint is efficacy of blood pressure control.

Treatment Angioplasty with plain old balloon, Angioplasty with paclitaxel eluting balloon
Clinical Study IdentifierNCT04366596
SponsorPeking Union Medical College Hospital
Last Modified on24 January 2021


Yes No Not Sure

Inclusion Criteria

age between 18y and 45y
with 60% stenosis in at least one renal artery
with hypertension (systolic blood pressure 140 mmHg or diastolic blood pressure 90 mmHg)
patients with no severe renal insufficiency (eGFR>30 ml/min, length of the kidney 7cm)
Good compliance
with informed consent

Exclusion Criteria

With apparent atherosclerotic risk factors
With renal intervention or surgery history
With congenital anatomical anomaly
With severe renal insufficiency (length of the target kidney < 7cm, total eGFR<30ml/min, divided eGFR of the target kidney<8 ml/min)
With contraindication for antiplatelet therapy
With severe cardiopulmonary insufficiency
Allergic to contrast medium
Being pregnant or preparing for pregnancy
With active cancer
Life expectancy < 12 month
Without informed consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note